Anteris Technologies Global Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVR research report →
Range $10 – $10
Price Chart
About the company
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve.
- CEO
- Wayne Geoffrey Paterson
- IPO
- 2024
- Employees
- 174
- HQ
- Eagan, MN, US
Get TickerSpark's AI analysis on AVR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $486.49M
- P/E
- -2.42
- PEG
- -0.05
- P/S
- 212.80
- P/B
- 2.19
- EV/EBITDA
- -2.64
- Div Yield
- 0.00%
- Gross Margin
- 39.28%
- Op Margin
- -4880.36%
- Net Margin
- -4637.86%
- ROE
- -57.19%
- ROIC
- -46.65%
Latest fiscal year · YoY change
- Revenue
- $1.91M-29.2%
- Gross Profit
- $-317,000-125.0%
- Op Income
- $-93,894,000
- Net Income
- $-94,144,000-23.4%
- EPS
- $-2.55+32.4%
- OCF Growth
- -27.0%
- FCF Growth
- -25.6%
- 52W High
- $11.06
- 52W Low
- $3.53
- 50D MA
- $6.63
- 200D MA
- $7.37
- Beta
- 0.73
- RSI (14)
- 34
- Avg Volume
- 1.17M
No earnings-call transcripts are available for AVR yet.
- Free Float
- 70.5%
- Shares Outstanding
- 97.49M
- Float Shares
- 68.76M
of shares held by institutions
145 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 8.48M | ▲ 1.62M |
| L1 Capital Pty Ltd | 7.79M | 0 |
| Sio Capital Management, LLC | 5.55M | ▲ 163.02K |
| Blackrock, Inc. | 5.45M | ▼ 320.79K |
| Perceptive Advisors LLC | 3.43M | 0 |
| Adar1 Capital Management, LLC | 3.15M | ▼ 644.04K |
| Ra Capital Management, L.P. | 3.00M | 0 |
| Bvf Inc/Il | 3.00M | 0 |
| Nantahala Capital Management, LLC | 2.76M | ▼ 623.53K |
| Geode Capital Management, LLC | 2.07M | ▼ 36.71K |
| Ensign Peak Advisors, Inc | 2.02M | ▼ 370.01K |
| State Street Corp | 1.95M | ▲ 245.08K |
Held by 112 ETFs
Biggest fund positions in AVR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | Schwartz Eric | other | 0 |
| Oct 6, 26 | L1 Capital Pty Ltd | buy | 272,695 |
| Oct 5, 26 | L1 Capital Pty Ltd | buy | 648,455 |
| Oct 2, 26 | L1 Capital Pty Ltd | buy | 236,354 |
| Oct 1, 26 | L1 Capital Pty Ltd | buy | 322,940 |
| Sep 30, 26 | L1 Capital Pty Ltd | buy | 74,286 |
| Sep 11, 26 | Moen Brent | other | 90,274 |
| Sep 11, 26 | Moen Brent | other | 0 |
| Aug 28, 26 | L1 Capital Pty Ltd | sell | 7,800 |
| Aug 19, 26 | St Denis David | other | 60,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVR coverage
Recent articles, reports, and earnings notes.
No research on AVR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVR report →Anteris' DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
globenewswire.com · Nov 22
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
globenewswire.com · Nov 16
NeurAxis (NASDAQ:NRXS) and Anteris Technologies Global (NASDAQ:AVR) Head-To-Head Review
defenseworld.net · Nov 14
Anteris Technologies Announces Results for the Third Quarter of 2026
globenewswire.com · Nov 10
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
globenewswire.com · Nov 1
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
globenewswire.com · Oct 27
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
proactiveinvestors.com · Oct 19
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
globenewswire.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.